API | bimekizumab

bimekizumab (Bimzelx) Report issue

Biologics mAb Approved ^FDA

AACT DrugBank

Active Ingredient History

NOW

Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Interleukin-17A (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

bimekizumab | ucb4940

Organizations (10)

Research & Development (10)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (1)

Psoriasis (approved 2023)

Experimental Indications - Clinical Trial Phases 1-4 (9)

Arthritis, Psoriatic (Phase 4)

Arthritis, Rheumatoid (Phase 2)

Axial Spondyloarthritis (Phase 3)

Dermatitis, Atopic (Phase 1/Phase 2)

Healthy Volunteers (Phase 1)

Hidradenitis Suppurativa (Phase 3)

Non-Radiographic Axial Spondyloarthritis (Phase 3)

Psoriasis (Phase 4)

Spondylitis, Ankylosing (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 40
# of Trial Organizations: 10

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue